HUP0400255A2 - Retinoid receptor ligandumok és kiválasztott citotoxikus szerek szinergikus kombinációi rák kezelésére - Google Patents

Retinoid receptor ligandumok és kiválasztott citotoxikus szerek szinergikus kombinációi rák kezelésére Download PDF

Info

Publication number
HUP0400255A2
HUP0400255A2 HU0400255A HUP0400255A HUP0400255A2 HU P0400255 A2 HUP0400255 A2 HU P0400255A2 HU 0400255 A HU0400255 A HU 0400255A HU P0400255 A HUP0400255 A HU P0400255A HU P0400255 A2 HUP0400255 A2 HU P0400255A2
Authority
HU
Hungary
Prior art keywords
retinoic acid
acid receptor
cytotoxic agent
selected cytotoxic
formula
Prior art date
Application number
HU0400255A
Other languages
English (en)
Hungarian (hu)
Inventor
Marco M. Gottardis
Matthew V. Lorenzi
Valérie Sandrine Vivat-Hannah
Fred Christopher Zusi
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0400255A2 publication Critical patent/HUP0400255A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0400255A 2001-03-22 2002-03-22 Retinoid receptor ligandumok és kiválasztott citotoxikus szerek szinergikus kombinációi rák kezelésére HUP0400255A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27775401P 2001-03-22 2001-03-22
PCT/US2002/008718 WO2002078620A2 (en) 2001-03-22 2002-03-22 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer

Publications (1)

Publication Number Publication Date
HUP0400255A2 true HUP0400255A2 (hu) 2004-08-30

Family

ID=23062213

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400255A HUP0400255A2 (hu) 2001-03-22 2002-03-22 Retinoid receptor ligandumok és kiválasztott citotoxikus szerek szinergikus kombinációi rák kezelésére

Country Status (15)

Country Link
EP (1) EP1383491A2 (cs)
JP (1) JP2004528316A (cs)
KR (1) KR20030086314A (cs)
CN (1) CN1498105A (cs)
BR (1) BR0207681A (cs)
CA (1) CA2441335A1 (cs)
CZ (1) CZ20032540A3 (cs)
DE (1) DE02733871T1 (cs)
ES (1) ES2214985T1 (cs)
HU (1) HUP0400255A2 (cs)
IL (1) IL157358A0 (cs)
MX (1) MXPA03008403A (cs)
PL (1) PL368946A1 (cs)
TR (1) TR200400812T3 (cs)
WO (1) WO2002078620A2 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer

Also Published As

Publication number Publication date
KR20030086314A (ko) 2003-11-07
DE02733871T1 (de) 2004-08-26
EP1383491A2 (en) 2004-01-28
MXPA03008403A (es) 2004-01-29
TR200400812T3 (tr) 2004-07-21
ES2214985T1 (es) 2004-10-01
CZ20032540A3 (cs) 2004-05-12
CN1498105A (zh) 2004-05-19
WO2002078620A2 (en) 2002-10-10
JP2004528316A (ja) 2004-09-16
BR0207681A (pt) 2004-07-27
IL157358A0 (en) 2004-02-19
CA2441335A1 (en) 2002-10-10
PL368946A1 (pl) 2005-04-04
WO2002078620A3 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
Bertram et al. Cancer prevention by retinoids and carotenoids: independent action on a common target
Leeman et al. STAT3 as a therapeutic target in head and neck cancer
Reynolds et al. Retinoid therapy of childhood cancer
Zusi et al. Selective retinoids and rexinoids in cancer therapy and chemoprevention
Heller et al. Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo
WO2008144475A1 (en) Methods and compositions for treating cancer
US11358933B2 (en) Compounds and methods for inhibiting CYP26 enzymes
JP2014076953A (ja) レチノイドｘ受容体パーシャルアゴニスト化合物及びこのレチノイドｘ受容体パーシャルアゴニスト化合物を有効成分として含有する薬剤
AU701790B2 (en) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
Vitoux et al. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response
US20110306671A1 (en) Amide derivatives of ethacrynic acid
Wozniak et al. Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells
Garcia-Bates et al. Role of peroxisome proliferator‐activated receptor gamma and its ligands in the treatment of hematological malignancies
JP5885140B2 (ja) Ｒｘｒパーシャルアゴニスト
Das et al. Anti-cancer potential of all-trans retinoic acid (ATRA): a review
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
Wallace et al. RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells
WO2012014936A1 (ja) 癌幹細胞の分化誘導剤
Marchwicka et al. Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review
WO2023242100A1 (en) Novel ras inhibitors
US6211239B1 (en) Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
WO2002078620A2 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
AU2002305072A1 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
US20070259829A1 (en) Uses of diphenyl/diphenylamine carboxylic acids
WO2011103563A1 (en) Methods and compositions for inhibiting and preventing the growth of malignant mast cells